IPS Heart Inc.’s ISX9-CPC received an FDA rare pediatric drug designation for cardiomyopathies associated with dystrophinopathies, positioning the program for incentives tied to pediatric development. The designation covers a pediatric-rare subset where treatment options remain limited. Separately, the ongoing U.S. regulatory landscape for advanced therapies continues to emphasize pathway navigation and pediatric evidence-building, with these designations often serving as early signals to investors about future trial-readiness and potential timing advantages. For families and clinicians, the designation does not guarantee approval, but it can support trial planning and potential exclusivity benefits tied to pediatric study performance.